These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38001905)

  • 1. Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature.
    Paolino G; Ramirez GA; Calabrese C; Moroni L; Bianchi VG; Bozzolo EP; Mercuri SR; Dagna L
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review.
    Khan MA; Khan FH; Khan HB; Saadeh C; Davey N
    Cureus; 2023 May; 15(5):e39553. PubMed ID: 37378095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.
    Bao A; Petri MA; Fava A; Kang J
    Lupus Sci Med; 2023 Dec; 10(2):. PubMed ID: 38114267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anifrolumab for treatment of refractory cutaneous lupus erythematosus.
    Blum FR; Sampath AJ; Foulke GT
    Clin Exp Dermatol; 2022 Nov; 47(11):1998-2001. PubMed ID: 35844070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.
    Martín-Torregrosa D; Mansilla-Polo M; Morgado-Carrasco D
    Actas Dermosifiliogr; 2024 Jul; ():. PubMed ID: 38972582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
    Carter LM; Wigston Z; Laws P; Vital EM
    Br J Dermatol; 2023 Jul; 189(2):210-218. PubMed ID: 36944572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on clinical trials for cutaneous lupus erythematosus.
    Xie L; Lopes Almeida Gomes L; Stone CJ; Faden DF; Werth VP
    J Dermatol; 2024 Jul; 51(7):885-894. PubMed ID: 38491743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment With Voclosporin and Anifrolumab in a Patient With Lupus Nephritis and Refractory Discoid Lupus Erythematosus: A Case Report and Literature Review.
    Karagenova R; Vodusek Z; Krimins R; Krieger A; Timlin H
    Cureus; 2024 Mar; 16(3):e55321. PubMed ID: 38559540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach.
    Plüß M; Piantoni S; Wincup C; Korsten P
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood.
    Günther C; Wolf C; Fennen L; Rösing S; Beissert S; Aringer M; Lee-Kirsch MA
    Front Immunol; 2023; 14():1253279. PubMed ID: 37809086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
    Cho YM; Furie R
    Immunotherapy; 2024 Jan; 16(1):15-20. PubMed ID: 37877249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials.
    Lim D; Kleitsch J; Werth VP
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):257-273. PubMed ID: 37860982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the management of refractory cutaneous lupus erythematosus.
    Verdelli A; Corrà A; Mariotti EB; Aimo C; Ruffo di Calabria V; Volpi W; Quintarelli L; Caproni M
    Front Med (Lausanne); 2022; 9():941003. PubMed ID: 36213629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.